Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $43.00

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $43.00.

STOK has been the topic of a number of research reports. Canaccord Genuity Group dropped their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Wedbush lifted their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 target price for the company. Chardan Capital restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $32.71 on Tuesday. Stoke Therapeutics has a one year low of $12.86 and a one year high of $40.22. The business’s 50-day moving average price is $30.45 and its two-hundred day moving average price is $32.05. The company has a market capitalization of $2.11 billion, a P/E ratio of -9.79 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. On average, equities analysts anticipate that Stoke Therapeutics will post -3.5 EPS for the current year.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target on STOK to $40 while maintaining an “outperform” rating, signaling confidence in the company’s pipeline and potential upside. Wedbush raises Stoke Therapeutics price target
• Positive Sentiment: Chardan Capital reiterated a “buy” rating on Stoke Therapeutics, adding to the favorable analyst sentiment surrounding the biotechnology company. Chardan Capital buy rating
• Neutral Sentiment: Canaccord Genuity remained constructive on the shares but issued a more cautious price outlook, reflecting a mixed analyst view despite continued confidence in Stoke’s long-term prospects. Canaccord Genuity forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright cut its projected EPS for fiscal 2026 to a loss of $3.35 from $3.09, fiscal 2027 to a loss of $2.55 from $2.05, and fiscal 2028 to a loss of $1.78 from $0.67. It also reduced quarterly estimates to losses of $0.81 per share, indicating expectations for higher or more prolonged expenses. HC Wainwright earnings forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright’s broader outlook remains bearish for later years, with its FY2029 EPS forecast reportedly reduced to $1.55 from $1.63. The revisions highlight execution and commercialization risks for Stoke’s pipeline. HC Wainwright FY2029 forecast
• Negative Sentiment: Director Barry Ticho sold 7,176 shares worth approximately $208,000, reducing his direct holdings by 26%. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, its negative signaling value is limited, but it may still weigh modestly on sentiment. SEC insider sale filing

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 7,176 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $29.04, for a total value of $208,391.04. Following the completion of the sale, the insider owned 20,422 shares of the company’s stock, valued at $593,054.88. The trade was a 26.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total value of $43,637.15. Following the sale, the general counsel owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. This trade represents a 7.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 10,428 shares of company stock worth $306,919 over the last three months. Company insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in STOK. BlackRock Inc. acquired a new position in Stoke Therapeutics during the second quarter valued at approximately $192,307,000. RTW Investments LP lifted its stake in shares of Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after buying an additional 423,331 shares during the last quarter. Redmile Group LLC boosted its holdings in shares of Stoke Therapeutics by 3.2% during the 1st quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock worth $135,584,000 after buying an additional 130,050 shares during the period. Morgan Stanley boosted its holdings in shares of Stoke Therapeutics by 0.3% during the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after buying an additional 9,108 shares during the period. Finally, State Street Corp grew its stake in Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after buying an additional 1,072,176 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.